Johnson & Johnson Operating Income 2006-2020 | JNJ

Johnson & Johnson annual/quarterly operating income history and growth rate from 2006 to 2020. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Johnson & Johnson operating income for the quarter ending June 30, 2020 was $3.940B, a 44.04% decline year-over-year.
  • Johnson & Johnson operating income for the twelve months ending June 30, 2020 was $16.314B, a 14.17% decline year-over-year.
  • Johnson & Johnson annual operating income for 2019 was $17.328B, a 3.73% decline from 2018.
  • Johnson & Johnson annual operating income for 2018 was $17.999B, a 1.84% increase from 2017.
  • Johnson & Johnson annual operating income for 2017 was $17.673B, a 10.76% decline from 2016.
Johnson & Johnson Annual Operating Income
(Millions of US $)
2019 $17,328
2018 $17,999
2017 $17,673
2016 $19,803
2015 $19,196
2014 $20,563
2013 $15,471
2012 $13,775
2011 $12,361
2010 $16,947
2009 $15,755
2008 $16,929
2007 $13,283
2006 $14,587
2005 $13,116
Johnson & Johnson Quarterly Operating Income
(Millions of US $)
2020-06-30 $3,940
2020-03-31 $6,509
2019-12-31 $4,218
2019-09-30 $1,647
2019-06-30 $7,041
2019-03-31 $4,422
2018-12-31 $3,122
2018-09-30 $4,423
2018-06-30 $4,973
2018-03-31 $5,481
2017-12-31 $2,560
2017-09-30 $4,790
2017-06-30 $4,748
2017-03-31 $5,575
2016-12-31 $4,324
2016-09-30 $5,281
2016-06-30 $4,904
2016-03-31 $5,294
2015-12-31 $3,758
2015-09-30 $4,122
2015-06-30 $5,741
2015-03-31 $5,575
2014-12-31 $2,703
2014-09-30 $6,810
2014-06-30 $5,626
2014-03-31 $5,424
2013-12-31 $2,750
2013-09-30 $3,667
2013-06-30 $4,793
2013-03-31 $4,261
2012-12-31 $3,100
2012-09-30 $3,595
2012-06-30 $2,035
2012-03-31 $5,045
2011-12-31 $318
2011-09-30 $4,111
2011-06-30 $3,422
2011-03-31 $4,510
2010-12-31 $2,228
2010-09-30 $4,219
2010-06-30 $4,220
2010-03-31 $6,280
2009-12-31 $2,604
2009-09-30 $4,245
2009-06-30 $4,263
2009-03-31 $4,643
2008-12-31 $3,517
2008-09-30 $4,290
2008-06-30 $4,375
2008-03-31 $4,747
2007-12-31 $2,332
2007-09-30 $3,268
2007-06-30 $4,031
2007-03-31 $3,652
2006-12-31 $2,708
2006-09-30 $3,661
2006-06-30 $3,603
2006-03-31 $4,615
2005-12-31 $2,503
2005-09-30 $3,420
2005-06-30 $3,266
2005-03-31 $3,927
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $389.737B $82.059B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Roche Holding AG (RHHBY) Switzerland $293.115B 0.00
Pfizer (PFE) United States $213.329B 13.33
Merck (MRK) United States $204.641B 14.60
Novartis AG (NVS) Switzerland $188.566B 14.66
AbbVie (ABBV) United States $163.035B 9.93
Novo Nordisk (NVO) Denmark $152.167B 24.76
Eli Lilly (LLY) United States $146.340B 22.34
AstraZeneca (AZN) United Kingdom $145.338B 28.25
Sanofi (SNY) $127.486B 15.15
GlaxoSmithKline (GSK) United Kingdom $102.699B 13.47
Bayer (BAYRY) Germany $61.996B 8.94
H Lundbeck (HLUYY) Denmark $7.388B 12.84
Innoviva (INVA) United States $1.376B 6.59